Denmark. Demant A/S
|Date of agreement:||24 Mar 2023|
|Amount in DKK:||DKK 366 million|
|Amount in EUR:||EUR 49.2 million|
|NACE sector / loan type:||Research and development|
NIB provides an investment loan to co-finance Demant’s research and development programme for the years 2021-2022.
Demant is working on hearing solutions and implants together with different universities, research centers, and firms in Denmark, with the goal of improving both their technology and products.
The investment loan represents continuity in the long-term cooperation between NIB and Demant, as the Bank has provided a total of five loans to the company since 2015.
Demant is a leading global hearing healthcare company, with its headquarters in Denmark. The William Demant Foundation has the majority-ownership of the company. Demant’s offering ranges from hearing aids and hearing implants to diagnostic equipment, services and audio solutions. The company is listed on NASDAQ Copenhagen.
Fulfilment of NIB's mandate
The investment loan represents continuity in the long-term cooperation between NIB and Demant, providing financing for the company’s R&D expenditures during 2021-2022.
As Demant has established itself as an important player in the global hearing healthcare market, the R&D that is carried out by the company and subsequent commercialization efforts are likely to have a positive effect on to the life quality of people suffering from hearing disabilities, enabling them to fully participate in social and work life from which they otherwise would have been excluded.
NIB has not identified any significant environmental issues connected to the R&D programme.